Accurate outcome prediction after neo-adjuvant radio-chemotherapy for rectal cancer based on a TCP-based early regression index.
Adaptive radiotherapy
Magnetic resonance imaging
Modeling
Rectal cancer
Tumor control probability
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
10
04
2019
revised:
01
07
2019
accepted:
01
07
2019
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
25
7
2019
Statut:
epublish
Résumé
An early tumor regression index (ERI Data of 65 patients treated with an early regression-guided adaptive boosting technique (ART) were available. Overall, loco-regional relapse-free and distant metastasis-free survival (OS, LRFS, DMFS) were considered. Patients received 41.4 Gy in 18 fractions (2.3 Gy/fr), including ART concomitant boost on the residual GTV during the last 6 fractions (3 Gy/fr, D At a median follow-up of 47 months, OS, LRFS and DMFS were 94%, 95% and 78%. Due to too few events, multivariable analyses focused on DMFS: the resulting CONV_model included pathological complete remission or clinical complete remission followed by surgery refusal (HR: 0.15, p = 0.07) and 5-FU dose >90% (HR: 0.29, p = 0.03) as best predictors, with AUC = 0.75. REGR_model included ERI ERI
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
An early tumor regression index (ERI
MATERIALS AND METHODS
METHODS
Data of 65 patients treated with an early regression-guided adaptive boosting technique (ART) were available. Overall, loco-regional relapse-free and distant metastasis-free survival (OS, LRFS, DMFS) were considered. Patients received 41.4 Gy in 18 fractions (2.3 Gy/fr), including ART concomitant boost on the residual GTV during the last 6 fractions (3 Gy/fr, D
RESULTS
RESULTS
At a median follow-up of 47 months, OS, LRFS and DMFS were 94%, 95% and 78%. Due to too few events, multivariable analyses focused on DMFS: the resulting CONV_model included pathological complete remission or clinical complete remission followed by surgery refusal (HR: 0.15, p = 0.07) and 5-FU dose >90% (HR: 0.29, p = 0.03) as best predictors, with AUC = 0.75. REGR_model included ERI
CONCLUSION
CONCLUSIONS
ERI
Identifiants
pubmed: 31334366
doi: 10.1016/j.ctro.2019.07.001
pii: S2405-6308(19)30084-9
pmc: PMC6617292
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12-16Déclaration de conflit d'intérêts
None.
Références
Best Pract Res Clin Gastroenterol. 2016 Aug;30(4):629-39
pubmed: 27644910
Colorectal Dis. 2016 Mar;18(3):234-46
pubmed: 26531759
Radiother Oncol. 2011 Jan;98(1):126-33
pubmed: 21176986
Acta Oncol. 2012 Mar;51(3):318-24
pubmed: 22497434
Clin Cancer Res. 2018 Jan 15;24(2):259-265
pubmed: 28751442
Radiology. 2009 Mar;250(3):730-9
pubmed: 19244043
Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):281-7
pubmed: 7673015
Acta Oncol. 2016 Aug;55(8):939-42
pubmed: 27367444
Cancer. 2017 May 1;123(9):1497-1506
pubmed: 28295220
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):480-8
pubmed: 24662278
Radiother Oncol. 2018 Sep;128(3):548-556
pubmed: 30041962
J Clin Oncol. 2015 Jun 1;33(16):1797-808
pubmed: 25918296
J Clin Oncol. 2014 Jan 1;32(1):34-43
pubmed: 24276776
Dis Colon Rectum. 2013 Jun;56(6):698-703
pubmed: 23652742
Clin Colorectal Cancer. 2015 Dec;14(4):227-38
pubmed: 26170142
Acta Oncol. 2015 Nov;54(10):1729-36
pubmed: 25914930
Lancet Oncol. 2016 Feb;17(2):174-183
pubmed: 26705854
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
Radiother Oncol. 2017 Jul;124(1):104-109
pubmed: 28647399
Phys Med. 2015 Mar;31(2):167-72
pubmed: 25586933
Ann Surg Oncol. 2012 Sep;19(9):2842-52
pubmed: 22526897
BMC Cancer. 2018 Oct 20;18(1):1006
pubmed: 30342494
Semin Radiat Oncol. 2011 Jul;21(3):234-9
pubmed: 21645869
Radiother Oncol. 2018 Mar;126(3):437-442
pubmed: 29395287
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):67-72
pubmed: 23790770
J Clin Oncol. 2011 Dec 10;29(35):4633-40
pubmed: 22067400
J Clin Oncol. 2005 Dec 1;23(34):8688-96
pubmed: 16246976
Clin Radiol. 2018 Jun;73(6):555-563
pubmed: 29459138
Radiother Oncol. 2018 Sep;128(3):564-568
pubmed: 30196982
Lancet Oncol. 2015 Aug;16(8):919-27
pubmed: 26156652
Radiology. 2011 Sep;260(3):734-43
pubmed: 21673229
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Med Phys. 2013 Mar;40(3):034101
pubmed: 23464345
J Clin Oncol. 2011 Oct 1;29(28):3753-60
pubmed: 21876084